Clinical Trials Browser

Interventional × Ovarian Neoplasms × atezolizumab × Clear all

NCT02839707 2026-03-18

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2/3 Active not recruiting

444 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Phase 1/2 Suspended

BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03353831 2025-04-06

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Phase 3 Completed

Ovarian Neoplasms

NCT03206047 2025-03-13

Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1/2 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02891824 2025-02-11

ATALANTE

Phase 3 Completed

Ovarian Neoplasms

NCT02876510 2025-02-04

ACTolog

Phase 1 Completed

GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT03598270 2024-08-30

ANITA

Phase 3 Completed

Ovarian Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03695380 2023-08-14

A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer

Phase 1 Completed

Ovarian Neoplasms

NCT03363867 2023-08-07

BEACON

Phase 2 Unknown

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03073525 2023-04-05

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Phase 2 Completed

25 enrolled 15 charts

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT02659384 2023-03-14

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT03038100 2023-02-17

IMagyn050

Phase 3 Completed

1,301 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03394885 2021-08-12

AdORN

Phase 1/2 Completed

18 enrolled 15 charts

Ovarian Neoplasms